Kimyrsa
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $171,197 | 1,307 | 658 |
| 2023 | $320,139 | 3,030 | 1,502 |
| 2022 | $500,566 | 4,552 | 2,196 |
| 2021 | $86,456 | 1,746 | 1,034 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $409,910 | 210 | 38.0% |
| Food and Beverage | $279,392 | 10,076 | 25.9% |
| Consulting Fee | $240,627 | 46 | 22.3% |
| Travel and Lodging | $74,428 | 272 | 6.9% |
| Unspecified | $40,639 | 2 | 3.8% |
| Education | $33,362 | 29 | 3.1% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Anchoring Intermittent long acting antimicrobials to medication for opiod use disorder treatment to facilitate structure transitions of care for people who use drugs admitted to the hospital with invasive infections (AIM-STOP) | Melinta Therapeutics, LLC | $39,139 | 0 |
| Relative Exposure and Safety Study of Kimyrsa in ABSSSI Patients | Melinta Therapeutics, LLC | $1,500 | 0 |
Top Doctors Receiving Payments for Kimyrsa
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Anesthesiology | Lexington, MA | $158,100 | 10 |
| Unknown | — | Detroit, MI | $73,709 | 27 |
| , D.O | Infectious Disease | Tucker, GA | $69,170 | 117 |
| , DPM | Podiatrist | Mt Prospect, IL | $55,552 | 88 |
| , M.D | Infectious Disease | Rancho Santa Fe, CA | $42,503 | 18 |
| , M.D | Infectious Disease | Shreveport, LA | $41,554 | 77 |
| , M.D | Infectious Disease | Bridgeport, WV | $40,494 | 63 |
| , M.D | Infectious Disease | Playa Vista, CA | $33,391 | 54 |
| , M.D | Infectious Disease | Fort Wayne, IN | $32,043 | 48 |
| , MD | Infectious Disease | Fairfax, VA | $30,774 | 53 |
| , M.D | Infectious Disease | Victoria, TX | $29,336 | 46 |
| , M.D | Emergency Medicine | Houston, TX | $26,596 | 36 |
| , M.D | Infectious Disease | Temecula, CA | $24,770 | 47 |
| , MD | Internal Medicine | Whitesburg, KY | $18,523 | 28 |
| , M.D | Infectious Disease | Lansing, MI | $14,311 | 74 |
| , M.D | Internal Medicine | Chicago, IL | $13,749 | 12 |
| , MD | Infectious Disease | Cookeville, TN | $12,814 | 17 |
| , MD | Infectious Disease | Minot, ND | $11,037 | 26 |
| , D.P.M | Podiatrist | Atlanta, GA | $10,472 | 28 |
| , M.D | Internal Medicine | Kissimmee, FL | $7,773 | 10 |
| , M.D | Infectious Disease | Greenvale, NY | $6,803 | 15 |
| , MD | Infectious Disease | Robbinsdale, MN | $6,139 | 10 |
| , M.D | Infectious Disease | Torrance, CA | $5,991 | 7 |
| , DPM | Podiatrist | Cleveland, OH | $5,314 | 9 |
| , M.D | Infectious Disease | Bedford, TX | $5,091 | 18 |
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.1M
- Total Doctors 3,950
- Transactions 10,635
About Kimyrsa
Kimyrsa is a drug associated with $1.1M in payments to 3,950 healthcare providers, recorded across 10,635 transactions in the CMS Open Payments database. The primary manufacturer is Melinta Therapeutics, LLC.
Payment data is available from 2021 to 2024. In 2024, $171,197 was paid across 1,307 transactions to 658 doctors.
The most common payment nature for Kimyrsa is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($409,910, 38.0% of total).
Kimyrsa is associated with 2 research studies, including "Anchoring Intermittent long acting antimicrobials to medication for opiod use disorder treatment to facilitate structure transitions of care for people who use drugs admitted to the hospital with invasive infections (AIM-STOP)" ($39,139).